Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Fabrazyme advisory committee review not necessary

Nov. 6, 2000

ASRM 2000: hormonal effects, safety and pharmacokinetics of abarelix depot-F in endometriosis

Nov. 2, 2000

Recently issued patent covers Pfizer's newest sorbitol dehydrogenase inhibitors

Nov. 2, 2000

Lilly discovers novel polypeptide with potential in obesity Rx

Nov. 2, 2000

Cathepsin inhibitors synthesized at AxyS claimed for osteoporosis, etc.

Nov. 2, 2000

Enhanced bioavailability of water-insoluble MTP inhibitor achieved with new formulation

Nov. 2, 2000

P2Y2 receptor agonists show promise for treatment of vaginal dryness

Nov. 2, 2000

Subtype-selective estrogen receptor modulators described by Signal, AxyS

Oct. 30, 2000

Novel GH secretagogues claimed by BMS

Oct. 30, 2000

Novo Nordisk's new potassium channel openers specifically claimed for diabetes

Oct. 30, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...